NASDAQ:PMD Psychemedics (PMD) Stock Price, News & Analysis → This consistently signaled gains of 453%... 610%... and even 1036%... (From Insiders Exposed) (Ad) Free PMD Stock Alerts $2.93 -0.07 (-2.33%) (As of 04:38 PM ET) Add Compare Share Share Today's Range$2.88▼$3.0050-Day Range$2.92▼$3.4052-Week Range$2.06▼$5.63Volume14,242 shsAverage Volume12,929 shsMarket Capitalization$16.99 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Psychemedics alerts: Email Address Ad DTIWarning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…Watch the presentation here About Psychemedics Stock (NASDAQ:PMD)Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States and internationally. The company offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opiates, such as heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine, Fentanyl, and alcohol. Its testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time. The company offers its services to employers for applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. Psychemedics Corporation was incorporated in 1986 and is headquartered in Dallas, Texas.Read More PMD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PMD Stock News HeadlinesMarch 28, 2024 | investorplace.comPMD Stock Earnings: Psychemedics Reported Results for Q4 2023March 28, 2024 | globenewswire.comPsychemedics Corporation Reports 2023 Financial ResultsMarch 28, 2024 | DTI (Ad)Warning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…March 23, 2024 | americanbankingnews.comPsychemedics (NASDAQ:PMD) Share Price Crosses Above 200-Day Moving Average of $3.03March 21, 2024 | globenewswire.comPsychemedics Recognized as a Top 10 Employee Health Testing Services ProviderJanuary 3, 2024 | bizjournals.comSmall cap drug testing company relocates HQ to DFW from MassachusettsJanuary 2, 2024 | msn.comMassachusetts drug testing firm targeting fentanyl relocates corporate HQ to DallasJanuary 2, 2024 | markets.businessinsider.comPsychemedics Corporation Announces Relocation of Headquarters to Dallas, TexasMarch 28, 2024 | DTI (Ad)the most reliable asset on earth is making a comebackGlobal tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.November 10, 2023 | msn.comPsychemedics reports Q3 resultsNovember 9, 2023 | finance.yahoo.comPsychemedics Corporation Reports Third Quarter 2023 Financial ResultsNovember 9, 2023 | morningstar.comPsychemedics Corp PMDOctober 27, 2023 | finance.yahoo.comUnveiling the Future of Drug Testing: Psychemedics Introduces Advanced 5-Panel Drug ScreenSeptember 26, 2023 | benzinga.comPsychemedics Chief Revenue Officer Awarded $448K Worth of Stock OptionsSeptember 22, 2023 | benzinga.comPsychemedics Corporation Appoints Shannon Shoemaker as Chief Revenue OfficerSeptember 21, 2023 | msn.comDo You Get PMS? You Could Be Headed for Early Menopause, Study ShowsAugust 22, 2023 | benzinga.comPresident & CEO at Psychemedics Acquires Company Stock Options Worth 300,000 SharesAugust 18, 2023 | finance.yahoo.comPsychemedics Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 11, 2023 | marketwatch.comPsychemedics 2Q Loss Widens Amid Labor Shortage, SettlementAugust 11, 2023 | marketwatch.comPsychemedics Eliminates DividendAugust 11, 2023 | finance.yahoo.comPsychemedics Corporation Reports Second Quarter 2023 Financial ResultsJuly 12, 2023 | marketwatch.comPsychemedics Taps Brian Hullinger as Successor of Long-Time CEO Ray KubackiJuly 12, 2023 | finance.yahoo.comPsychemedics Corporation Announces CEO Succession PlanMay 19, 2023 | msn.comPsychemedics's Ex-Dividend Date Is Wednesday, Here's What You Need To KnowMay 19, 2023 | finance.yahoo.comDo These 3 Checks Before Buying Psychemedics Corporation (NASDAQ:PMD) For Its Upcoming DividendMay 13, 2023 | finance.yahoo.comPsychemedics (NASDAQ:PMD) Is Paying Out A Dividend Of $0.07May 12, 2023 | msn.comPsychemedics (PMD) Declares $0.07 DividendSee More Headlines Receive PMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Psychemedics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/23/2019Today3/28/2024Next Earnings (Estimated)4/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNASDAQ:PMD CUSIPN/A CIK806517 Webwww.psychemedics.com Phone(978) 206-8220Fax978-264-9236Employees133Year Founded1985Profitability EPS (Most Recent Fiscal Year)($0.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,080,000.00 Net Margins-16.69% Pretax Margin-12.82% Return on Equity-40.62% Return on Assets-22.68% Debt Debt-to-Equity Ratio0.01 Current Ratio1.46 Quick Ratio1.46 Sales & Book Value Annual Sales$25.24 million Price / Sales0.70 Cash Flow$0.40 per share Price / Cash Flow7.59 Book Value$1.91 per share Price / Book1.60Miscellaneous Outstanding Shares5,800,000Free Float4,410,000Market Cap$17.69 million OptionableNot Optionable Beta0.64 Social Links 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Brian HullingerPresident, CEO & DirectorDr. Werner A. Baumgartner Ph.D.FounderMs. Annette BaumgartnerFounderDaniella MehalikVice President of FinanceMr. Michael Weisenhoff (Age 34)Principal Financial & Accounting Manager Ms. Shannon ShoemakerChief Revenue OfficerMr. Patrick J. Kinney Jr.SecretaryMore ExecutivesKey CompetitorsCentogeneNASDAQ:CNTGBioNexus Gene LabNASDAQ:BGLCDermTechNASDAQ:DMTKExagenNASDAQ:XGNOpGenNASDAQ:OPGNView All CompetitorsInsiders & InstitutionsCitadel Advisors LLCSold 4,238 shares on 2/15/2024Ownership: 0.279%Charles M DoucotSold 12,700 sharesTotal: $59,182.00 ($4.66/share)View All Insider TransactionsView All Institutional Transactions PMD Stock Analysis - Frequently Asked Questions How have PMD shares performed in 2024? Psychemedics' stock was trading at $2.96 on January 1st, 2024. Since then, PMD stock has decreased by 0.3% and is now trading at $2.95. View the best growth stocks for 2024 here. Are investors shorting Psychemedics? Psychemedics saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 14,800 shares, an increase of 27.6% from the February 29th total of 11,600 shares. Based on an average daily trading volume, of 13,300 shares, the short-interest ratio is currently 1.1 days. Currently, 0.4% of the company's stock are sold short. View Psychemedics' Short Interest. When is Psychemedics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 2nd 2024. View our PMD earnings forecast. How were Psychemedics' earnings last quarter? Psychemedics Co. (NASDAQ:PMD) announced its quarterly earnings results on Tuesday, April, 23rd. The company reported $0.11 earnings per share (EPS) for the quarter. The company earned $9.82 million during the quarter. Psychemedics had a negative trailing twelve-month return on equity of 40.62% and a negative net margin of 16.69%. How often does Psychemedics pay dividends? What is the dividend yield for Psychemedics? Psychemedics declared a quarterly dividend on Tuesday, May 9th. Shareholders of record on Thursday, May 25th will be paid a dividend of $0.07 per share on Thursday, June 8th. This represents a $0.28 annualized dividend and a dividend yield of 9.49%. The ex-dividend date is Wednesday, May 24th. Read our dividend analysis for PMD. What is Raymond C. Kubacki Jr.'s approval rating as Psychemedics' CEO? 6 employees have rated Psychemedics Chief Executive Officer Raymond C. Kubacki Jr. on Glassdoor.com. Raymond C. Kubacki Jr. has an approval rating of 67% among the company's employees. What other stocks do shareholders of Psychemedics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Psychemedics investors own include Zynerba Pharmaceuticals (ZYNE), Dominion Energy (D), Sorrento Therapeutics (SRNE), AT&T (T), AbbVie (ABBV), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pattern Energy Group (PEGI) and Simon Property Group (SPG). Who are Psychemedics' major shareholders? Psychemedics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Citadel Advisors LLC (0.28%). Insiders that own company stock include Charles M Doucot and Peter Kamin. View institutional ownership trends. How do I buy shares of Psychemedics? Shares of PMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PMD) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryMost important medical advance in 100 yearsThe Oxford ClubFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Psychemedics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.